Yueyu Dai1, Fangyuan Zhong1, Wenbin Liu2, Qibin Song3, Weiguo Hu4. 1. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China. 2. College of Health Sciences and Nursing, Wuhan Polytechnic University, Wuhan, 430023, People's Republic of China. 3. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China. qibinsong@whu.edu.cn. 4. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, People's Republic of China. hwg74@163.com.
Abstract
PURPOSE: To explore the relationship between Mycoplasma hyorhinis infection and tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients. METHODS: Mycoplasma hyorhinis infection can be verified with the monoclonal antibody PD4, which specifically recognizes a distinct protein of M. hyorhinis. Immunohistochemistry (IHC), using PD4 to detect M. hyorhinis, was performed on paraffin-embedded lung adenocarcinoma tissues of patients who had epidermal growth factor (EGFR) mutations and had received oral TKI. The number of patients enrolled in our study was 101. Assessments following TKI treatment were performed until objective disease progression or stable disease at the cutoff date was reached. In all of the patients, the primary endpoint was investigator-assessed progression-free survival (PFS). RESULTS: Immunohistochemistry revealed that 61 of 101 cases (60.4%) of lung adenocarcinoma were positive for M. hyorhinis, which comprised of 31 low-positive cases and 30 high-positive cases; the remaining 40 cases (39.6%) were negative. The median PFS was significantly longer in the negative group [18 months (95% CI 14.15-21.85)] than in the low-positive group [10 months (95% CI 7.70-12.30); hazard ratio (HR) 4.095, 95% CI 2.254-7.438; p < 0.001] and in the high-positive group [4 months (95% CI 2.85-5.15); HR 31.703, 95% CI 14.425-69.678; p < 0.001]. The results of the subgroup analysis were satisfactory. The PFS benefit with negative M. hyorhinis infection was consistent across subgroups. CONCLUSIONS: In this retrospective, exploratory analysis, M. hyorhinis infection significantly reduced PFS. With increased levels of M. hyorhinis infection, the progression of the disease was more advanced, likely due to the hydrolysis of TKI by M. hyorhinis. A strong correlation was found between M. hyorhinis infection and TKI resistance in lung adenocarcinoma. This study provides potent evidence that M. hyorhinis hydrolyses TKI and will assist in the research of related mechanisms in the future. IMPLICATIONS FOR CANCER SURVIVORS: It provides an option to improve the efficacy of TKI, including strategies to decrease M. hyorhinis infection, thereby reducing long-term distress in TKI resistance patients with EGFR mutations.
PURPOSE: To explore the relationship between Mycoplasma hyorhinisinfection and tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinomapatients. METHODS:Mycoplasma hyorhinisinfection can be verified with the monoclonal antibody PD4, which specifically recognizes a distinct protein of M. hyorhinis. Immunohistochemistry (IHC), using PD4 to detect M. hyorhinis, was performed on paraffin-embedded lung adenocarcinoma tissues of patients who had epidermal growth factor (EGFR) mutations and had received oral TKI. The number of patients enrolled in our study was 101. Assessments following TKI treatment were performed until objective disease progression or stable disease at the cutoff date was reached. In all of the patients, the primary endpoint was investigator-assessed progression-free survival (PFS). RESULTS: Immunohistochemistry revealed that 61 of 101 cases (60.4%) of lung adenocarcinoma were positive for M. hyorhinis, which comprised of 31 low-positive cases and 30 high-positive cases; the remaining 40 cases (39.6%) were negative. The median PFS was significantly longer in the negative group [18 months (95% CI 14.15-21.85)] than in the low-positive group [10 months (95% CI 7.70-12.30); hazard ratio (HR) 4.095, 95% CI 2.254-7.438; p < 0.001] and in the high-positive group [4 months (95% CI 2.85-5.15); HR 31.703, 95% CI 14.425-69.678; p < 0.001]. The results of the subgroup analysis were satisfactory. The PFS benefit with negative M. hyorhinisinfection was consistent across subgroups. CONCLUSIONS: In this retrospective, exploratory analysis, M. hyorhinisinfection significantly reduced PFS. With increased levels of M. hyorhinisinfection, the progression of the disease was more advanced, likely due to the hydrolysis of TKI by M. hyorhinis. A strong correlation was found between M. hyorhinisinfection and TKI resistance in lung adenocarcinoma. This study provides potent evidence that M. hyorhinis hydrolyses TKI and will assist in the research of related mechanisms in the future. IMPLICATIONS FOR CANCER SURVIVORS: It provides an option to improve the efficacy of TKI, including strategies to decrease M. hyorhinisinfection, thereby reducing long-term distress in TKI resistance patients with EGFR mutations.
Authors: Uljana A Boyarskikh; Alexandra S Shadrina; Mariya A Smetanina; Yakov A Tsepilov; Igor P Oscorbin; Vadim V Kozlov; Alexander E Kel; Maxim L Filipenko Journal: J Cancer Res Clin Oncol Date: 2018-05-08 Impact factor: 4.553
Authors: Leore T Geller; Michal Barzily-Rokni; Tal Danino; Oliver H Jonas; Noam Shental; Deborah Nejman; Nancy Gavert; Yaara Zwang; Zachary A Cooper; Kevin Shee; Christoph A Thaiss; Alexandre Reuben; Jonathan Livny; Roi Avraham; Dennie T Frederick; Matteo Ligorio; Kelly Chatman; Stephen E Johnston; Carrie M Mosher; Alexander Brandis; Garold Fuks; Candice Gurbatri; Vancheswaran Gopalakrishnan; Michael Kim; Mark W Hurd; Matthew Katz; Jason Fleming; Anirban Maitra; David A Smith; Matt Skalak; Jeffrey Bu; Monia Michaud; Sunia A Trauger; Iris Barshack; Talia Golan; Judith Sandbank; Keith T Flaherty; Anna Mandinova; Wendy S Garrett; Sarah P Thayer; Cristina R Ferrone; Curtis Huttenhower; Sangeeta N Bhatia; Dirk Gevers; Jennifer A Wargo; Todd R Golub; Ravid Straussman Journal: Science Date: 2017-09-15 Impact factor: 47.728
Authors: M Raymond V Finlay; Mark Anderton; Susan Ashton; Peter Ballard; Paul A Bethel; Matthew R Box; Robert H Bradbury; Simon J Brown; Sam Butterworth; Andrew Campbell; Christopher Chorley; Nicola Colclough; Darren A E Cross; Gordon S Currie; Matthew Grist; Lorraine Hassall; George B Hill; Daniel James; Michael James; Paul Kemmitt; Teresa Klinowska; Gillian Lamont; Scott G Lamont; Nathaniel Martin; Heather L McFarland; Martine J Mellor; Jonathon P Orme; David Perkins; Paula Perkins; Graham Richmond; Peter Smith; Richard A Ward; Michael J Waring; David Whittaker; Stuart Wells; Gail L Wrigley Journal: J Med Chem Date: 2014-10-01 Impact factor: 7.446